- Home
- BCRX
as 03-26-2025 3:30pm EST
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
| Founded: | 1986 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 1.7B | IPO Year: | 1994 |
| Target Price: | $15.67 | AVG Volume (30 days): | 3.8M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.03 - $9.50 | Next Earning Date: | 05-05-2025 |
| Revenue: | $450,712,000 | Revenue Growth: | 36.00% |
| Revenue Growth (this year): | 27.66% | Revenue Growth (next year): | 13.59% |
Latest BioCryst Pharmaceuticals Inc. News
BCRX Breaking Stock News: Dive into BCRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%
GlobeNewswire
21 days ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
23 days ago
BioCryst Pharmaceuticals CFO Anthony Doyle to Step Down
Insider Monkey
a month ago
Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?
Zacks
a month ago
BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks
a month ago
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher
Zacks
a month ago
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know
Simply Wall St.
a month ago
Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly Results
Compare BCRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCRX BioCryst Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.